Vir pressures Gilead with hepatitis D cocktail showing early efficacy in phase 2

Vir Biotechnology's hepatitis D combination therapy has shown early efficacy in results from a phase 2 trial, suggesting the drug cocktail may pose a threat to Gilead Sciences' stuttering attempt to capture the market.